ClinicalTrials.gg

Program

Lutetium-177

Also written as “[177Lu]Lu-NeoB”, “[177Lu]Lu-PSMA-617” and “Lutetium[177Lu] Oxodotreotide Injection”.

In Novartis's pipeline, Radioligand therapy target HER2. Its studies are mostly in Prostatic Neoplasms · Breast Neoplasms · Neuroendocrine Tumors · Glioblastoma · Carcinoma, Non-Small-Cell Lung, led by 11 companies.

Furthest: phase 3, since Dec 16, 202024 company-led studies, 20 open or runningNext primary completion: Dec 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Novartis108 open or runningphase 2since Dec 16, 2020Dec 16, 2020Dec 30, 2026phase 1 · NCT05870579
Sinotau Pharmaceutical Group32 open or runningphase 3since Jul 5, 2022Jul 5, 2022Jun 1, 2027phase 3 · NCT06398444
Bracco21 open or runningphase 2since May 20, 2022May 20, 2022none ahead
Sichuan Biokin Pharmaceutical22 open or runningphase 1since Nov 14, 2025Nov 14, 2025Dec 2027phase 1 · NCT07232407
Affibody11 open or runningphase 1since Jun 23, 2025Jun 23, 2025Jan 1, 2027phase 1 · NCT07081555
Alpha-9 Oncology USA11 open or runningphase 1since Jun 9, 2026Jun 9, 2026Dec 2028phase 1 · NCT07661641
Cellbion11 open or runningphase 1since Nov 14, 2025Nov 14, 2025Apr 2029phase 1 · NCT07244393
futurechem11 open or runningphase 2since Jun 10, 2022Jun 10, 2022none ahead
Jiangsu HengRui Medicine11 open or runningphase 3since May 22, 2023May 22, 2023Dec 2026phase 3 · NCT05884255
Philogen11 open or runningphase 1since Oct 10, 2024Oct 10, 2024May 31, 2028phase 1 · NCT06640413
Spago Nanomedical AB11 open or runningphase 2since Dec 6, 2023Dec 6, 2023Dec 1, 2027phase 2 · NCT06184035

Also a collaborator on its studies: Merck, psi-cro, baili-bio-chengdu-pharmaceutical-co-ltd and medpace-inc.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 9 studies since Dec 16, 2020.

  1. Aug 25, 2023Phase 2 study in Prostatic NeoplasmsSinotau Pharmaceutical Group · NCT06081686 · 32 planned · China
  2. Dec 6, 2023Spago Nanomedical AB's first study: phase 2 study in Neoplasm MetastasisNew to Spago Nanomedical ABSpago Nanomedical AB · NCT06184035 · 90 planned · Australia
  3. Jan 17, 2024Phase 2 study in Breast NeoplasmsNovartis · NCT06247995 · 20 enrolled · United States, Australia, Canada and more
  4. Mar 4, 2024Phase 1 study in Metastatic Neuroendocrine Prostate CancerNovartis · NCT06379217 · 31 enrolled · United States, France, Germany and more
  5. May 1, 2024Phase 3 study in Advanced Neuroendocrine NeoplasmSinotau Pharmaceutical Group · NCT06398444 · 85 planned · China
  6. Jun 17, 2024Early phase 1 study in Prostatic NeoplasmsBracco · NCT06516510 · 17 enrolled · United States, Netherlands, Spain
  7. Aug 16, 2024Phase 1 study in Carcinoma, Non-Small-Cell LungNovartis · NCT06562192 · 162 planned · United States, Belgium, Canada and more
  8. Oct 10, 2024Philogen's first study: phase 1 study in FAPNew to PhilogenPhilogen · NCT06640413 · 56 planned · Italy
  9. Feb 25, 2025Phase 2 study in Prostatic NeoplasmsNovartis · NCT06881823
  10. Jun 23, 2025Affibody's first study: phase 1 study in Breast NeoplasmsNew to AffibodyAffibody · NCT07081555 · 21 planned · Sweden
  11. Nov 14, 2025Cellbion's first study: phase 1 study in Metastatic Castration-resistant Prostate Cancer (mCRPC)New to CellbionCellbion · NCT07244393 · 30 planned · South Korea
  12. Nov 14, 2025Sichuan Biokin Pharmaceutical's first studies: 2 phase 1 studiesNew to Sichuan Biokin PharmaceuticalSichuan Biokin Pharmaceutical · NCT07232407, NCT07274852
  13. Jun 9, 2026Alpha-9 Oncology USA's first study: phase 1 study in Breast NeoplasmsNew to Alpha-9 Oncology USAAlpha-9 Oncology USA · NCT07661641 · 115 planned · Australia
  14. Jun 15, 2026Phase 1 study in Breast NeoplasmsNovartis · NCT07660055 · 156 planned · United States, Australia, Canada and more

Ahead

  1. Dec 2026Primary completion: phase 3 study in Advanced Gastroenteropancreatic Neuroendocrine TumorJiangsu HengRui Medicine · NCT05884255
  2. Dec 30, 2026Primary completion: phase 1 study in Breast NeoplasmsNovartis · NCT05870579
  3. Jan 1, 2027Primary completion: phase 1 study in Breast NeoplasmsAffibody · NCT07081555
  4. Apr 14, 2027Primary completion: phase 2 study in Breast NeoplasmsNovartis · NCT06247995

TargetBeta

“Radioligand therapy target HER2”the company's pipeline, read by Claude · source
“Radioligand therapy target FAP”the company's pipeline, read by Claude · source

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
Gallium-68Philogenphase 317

Studies

All 24 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07660055Breast Neoplasms · United States, Australia, Canada and more1RecruitingNovartisMay 24, 2032156
NCT07661641Breast Neoplasms · Australia1RecruitingAlpha-9 Oncology USADec 2028115
NCT07274852Lung Neoplasms · China1RecruitingSichuan Biokin PharmaceuticalDec 202722
NCT07244393Metastatic Castration-resistant Prostate Cancer (mCRPC) · South Korea1RecruitingCellbionApr 202930
NCT07232407Digestive System Neoplasms · China1RecruitingSichuan Biokin PharmaceuticalDec 202722
NCT07081555Breast Neoplasms · Sweden1RecruitingAffibodyJan 1, 202721
NCT06881823Prostatic Neoplasms2WithdrawnNovartisMar 31, 20300
NCT06640413FAP · Italy1RecruitingPhilogenMay 31, 202856
NCT06562192Carcinoma, Non-Small-Cell Lung · United States, Belgium, Canada and more1RecruitingNovartisJan 15, 2031162
NCT06516510Prostatic Neoplasms · United States, Netherlands, SpainEarly 1TerminatedBraccoAug 15, 202517
NCT06398444Advanced Neuroendocrine Neoplasm · China3RecruitingSinotau Pharmaceutical GroupJun 1, 202785
NCT06379217Metastatic Neuroendocrine Prostate Cancer · United States, France, Germany and more1Active, not recruitingNovartisOct 9, 202631
NCT06247995Breast Neoplasms · United States, Australia, Canada and more2Active, not recruitingNovartisApr 14, 202720
NCT06184035Neoplasm Metastasis · Australia2RecruitingSpago Nanomedical ABDec 1, 202790
NCT06081686Prostatic Neoplasms · China2RecruitingSinotau Pharmaceutical GroupDec 31, 202732
NCT05884255Advanced Gastroenteropancreatic Neuroendocrine Tumor · China3RecruitingJiangsu HengRui MedicineDec 2026220
NCT05870579Breast Neoplasms · United States, China, France and more1Active, not recruitingNovartisDec 30, 202628
NCT05739942Glioblastoma · United States, France, Germany and more1Active, not recruitingNovartisAug 10, 202742
NCT05658003Metastatic Castration-Resistant Prostate Cancer (mCRPC) · China2Active, not recruitingNovartisDec 2, 202463
NCT05670106Metastatic Castration-Resistant Prostate Cancer (mCRPC) · China2CompletedNovartisMay 17, 202462
NCT05459844Neuroendocrine Tumors · China3CompletedSinotau Pharmaceutical GroupJun 26, 2025196
NCT05458544Metastatic Castration-resistant Prostate Cancer · United States2RecruitingfuturechemJun 1, 202526
NCT05413850Prostatic Neoplasms · United States, Belgium, Germany and more2RecruitingBraccoAug 27, 202682
NCT04711135Pheochromocytoma · United States, France, Poland and more2Active, not recruitingNovartisMar 12, 202411

How it is read

Names in the registry

  • “[177Lu]Lu-NeoB”, 4 entries
  • “[177Lu]Lu-PSMA-617”, 3 entries
  • “Lutetium[177Lu] Oxodotreotide Injection”, 2 entries
  • “Lutetium [177Lu] BL-ARC001”, 2 entries
  • “Phase I:[177Lu]Lu-XT033 Injection”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.